This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
PYROXD1 · Western blot design guide
PYROXD1 Western Blot Planning Guide
Plan a PYROXD1 Western blot around the catalog-observed 55.8 kDa band, image-backed A17214-3 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
PYROXD1 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 55.8 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Adipose tissue | |
| Negative control | Spleen |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 55.8 kDa |
| ⓘ | Localization | Nucleus / Cytoplasm, cytosol |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated PYROXD1 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Adipose tissue |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A17214-3 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected PYROXD1 Western Blot Band Size?
Use the product-observed 55.8 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 55.8 kDa | Matches the authoritative product WB observation. |
| 55.8 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected PYROXD1 appearancePlan around 55.8 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 55.8 kDa; use this as the primary experimental expectation. |
| Calculated mass | 55.8 kDa from UniProt Q8WU10; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A17214-3. |
| Situation | Likely cause | Next action |
|---|---|---|
| 55.8 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing PYROXD1 band
A17214-3 · PYROXD1
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for PYROXD1 Western blot
🧪Use Adipose tissue as the first positive-control candidate and Spleen as the HPA Not detected negative candidate.
Positive control: Adipose tissue (Medium)
Negative control: Spleen (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for PYROXD1
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Breast | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Adrenal gland | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Appendix | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Spleen | Reported tissue cells | Not detected | Protein (HPA) | HPA → |
Section 3
Advanced PYROXD1 Western Blot Tips
Deeper troubleshooting and optimisation questions for PYROXD1, answered from its protein features.
Which band should guide the blot?
Use 55.8 kDa, the observation attached to the authoritative A17214-3 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 55.8 kDa expectation.
Which positive control should I start with?
Start with Adipose tissue, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Spleen as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for PYROXD1 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A17214-3 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
PYROXD1 Western Blot Reagents
Human/Mouse/Rat-reactive PYROXD1 Western blot reagents with authoritative product imagery.
Real WB data
Anti-PYROXD1 Antibody Picoband®
Cat # A17214-3
Real WB data
Anti-PYROXD1 Antibody Picoband®
Cat # A17214-4
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q8WU10
- Human Protein Atlas — PYROXD1
- A17214-3 product record
- PMC9637080 — Crosstalk between ROCK1 and PYROXD1 regulates CAFs activation and promotes laryngeal squamous cell carcinoma metastasis (Discover oncology, 2022)
- PMC13059403 — Pyroxd1 is essential for murine viability with the homozygous N155S recurrent variant linked to myopathy, muscle hypotrophy and osteopenia (Acta neuropathologica communications, 2026)
- PMC10244218 — Connective tissue presentation in two families expands the phenotypic spectrum of PYROXD1 disorders (Human molecular genetics, 2023)